As­traZeneca dou­bles down on dig­i­tal health in its lat­est col­lab­o­ra­tion

As­traZeneca is go­ing down the dig­i­tal health route in its newest deal, fo­cus­ing on de­cen­tral­ized clin­i­cal tri­als and vir­tu­al health­care.

The UK phar­ma has teamed up again with dig­i­tal health firm Hu­ma Ther­a­peu­tics in a bid to “scale in­no­va­tion for dig­i­tal health,” Hu­ma said in a state­ment ear­ly Wednes­day.

As­traZeneca put rough­ly $33 mil­lion in­to the deal, ac­cord­ing to a re­port from CN­BC — as the com­pa­nies have re­mained mum on oth­er fi­nan­cial specifics. The small com­pa­ny al­ready raised mon­ey last year in a Se­ries C to the tune of $130 mil­lion — led by Leaps by Bay­er and Hi­tachi Ven­tures. That fund­ing was to ex­pand its dig­i­tal plat­form in the US, Asia and the Mid­dle East. There was an ad­di­tion­al com­mit­ment of $70 mil­lion that can be ex­er­cised at a lat­er date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER